Tandem Diabetes Care (TNDM) FY2018 results: revenue $184 million, up 70.9% on the year
Tandem Diabetes Care Inc. (TNDM) reported revenue of $184 million for fiscal 2018, the year ended 31 December 2018, up 70.9% on the year before. Net income was -$123 million, and diluted earnings per share $-2.55. The figures are the company's own, from the 10-K it filed with the SEC on 26 February 2019.
Revenue
$184 million
+70.9% on the year
FY2012FY2018
Operating margin
-24.3%
-58.5% a year earlier
FY2012FY2018
Net income
-$123 million
FY2012FY2018
Diluted EPS
-$2.55
FY2012FY2018
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Revenue
184
108
84.2
+70.9%
Cost of revenue
94.0
63.5
60.7
+48.1%
Gross profit
89.8
44.1
23.6
+103.7%
Gross margin
48.9%
41.0%
28.0%
Research and development
29.2
20.7
18.8
+41.5%
Selling, general and administrative
105
86.4
82.8
+21.8%
Operating income
-44.6
-62.9
-78.1
Operating margin
-24.3%
-58.5%
-92.6%
Pre-tax income
-123
-73.0
-83.5
Income tax
0.1
0.0
-0.0
+537.5%
Net income
-123
-73.0
-83.4
Net margin
-66.7%
-67.9%
-99.0%
Diluted EPS
-$2.55
-$12.87
-$27.30
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Operating cash flow
-8.3
-66.1
-61.2
Capital expenditure
3.0
5.7
8.9
-47.8%
Free cash flow
-11.3
-71.9
-70.1
Free cash flow margin
-6.1%
-66.8%
-83.2%
Cash from investing
-90.7
2.8
10.4
Cash from financing
117
40.4
52.3
+190.2%
Depreciation and amortisation
5.8
6.9
5.5
-15.2%
Share-based compensation
23.7
12.6
11.7
+88.0%
Shares outstanding at period end
58m
10m
3m
+468.8%
Balance sheet
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Shareholders' equity
131
-29.1
-5.9
Debt
0.0
82.7
81.1
Other liabilities
75.0
41.8
37.2
+79.7%
Total liabilities and equity
206
95.3
112
+116.4%
Fixed assets
17.2
19.6
18.4
-12.6%
Investments
87.2
0.5
8.9
+18,104.8%
Cash and equivalents
41.8
13.7
44.7
+205.3%
Receivables
35.2
20.8
11.2
+69.3%
Inventory
19.9
27.0
21.2
-26.3%
Other assets
5.0
13.8
8.1
-63.4%
Total assets
206
95.3
112
+116.4%
10-K for the year ended 31 December 2018, filed 26 February 2019: the filing.